Xhosa
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Iintlobo zeemveliso
iveliso ezifakiwe
Iipilisi zeLenopril ezixhobisa uLawulo lweGazi kunye nempilo ye-Cardiovascular Health

Iipilisi zeLenopril ezixhobisa uLawulo lweGazi kunye nempilo ye-Cardiovascular Health
I-Telmisartan Ingcono i-antihypertensive Ukukhusela izintso

I-Telmisartan Ingcono i-antihypertensive Ukukhusela izintso
I-Flumazenil I-Antagonist ekhethiweyo ye-GABAA ye-Receptor kunye nezicelo zayo zonyango

I-Flumazenil I-Antagonist ekhethiweyo ye-GABAA ye-Receptor kunye nezicelo zayo zonyango
I-Trametinib Kinase Inhibitor Ijolise kwi-BRAF V600 yoGuquko-Positive Cancers

I-Trametinib Kinase Inhibitor Ijolise kwi-BRAF V600 yoGuquko-Positive Cancers
I-Dabrafenib Unyango olujolisiweyo lwe-BRAF-Mutated Cancers

I-Dabrafenib Unyango olujolisiweyo lwe-BRAF-Mutated Cancers
I-Tirzepatide Dual GLP-1 kunye ne-GIP Receptor Agonist yoLawulo lobunzima kunye noLawulo lweGlycemic

I-Tirzepatide Dual GLP-1 kunye ne-GIP Receptor Agonist yoLawulo lobunzima kunye noLawulo lweGlycemic
Cisapride Gastric Stimulant for Indigestion and Digestive Disorders

Cisapride Gastric Stimulant for Indigestion and Digestive Disorders
I-YK-11 ye-SARM enamandla kwiZakhiwo ze-Muscle, ukuzuza amandla, kunye ne-Myostatin Inhibition

I-YK-11 ye-SARM enamandla kwiZakhiwo ze-Muscle, ukuzuza amandla, kunye ne-Myostatin Inhibition
I-Ostarine (MK-2866) i-SARM eNqabileyo yokuKhula kweMuscle, ukuLahla kwaManqatha, kunye nokuBuyiswa koMzimba

I-Ostarine (MK-2866) i-SARM eNqabileyo yokuKhula kweMuscle, ukuLahla kwaManqatha, kunye nokuBuyiswa koMzimba
I-MK-677 i-Compound ekhethekileyo yokuKhula kweZihlunu, ukunyamezela, kunye nokuBuyisa

I-MK-677 i-Compound ekhethekileyo yokuKhula kweZihlunu, ukunyamezela, kunye nokuBuyisa
0102030405
I-Tirzepatide Dual GLP-1 kunye ne-GIP Receptor Agonist yoLawulo lobunzima kunye noLawulo lweGlycemic
I-Tirzepatide Dual GLP-1 kunye ne-GIP Receptor Agonist yoLawulo lobunzima kunye noLawulo lweGlycemic
I-Tirzepatide Dual GLP-1 kunye ne-GIP Receptor Agonist yoLawulo lobunzima kunye noLawulo lweGlycemic
I-Tirzepatide Dual GLP-1 kunye ne-GIP Receptor Agonist yoLawulo lobunzima kunye noLawulo lweGlycemic

I-Tirzepatide Dual GLP-1 kunye ne-GIP Receptor Agonist yoLawulo lobunzima kunye noLawulo lweGlycemic

Ixabiso lokubhekisela: USD 300-600/g

  • Igama lemveliso Tirzepatide
  • Inombolo yeCAS. 2023788-19-2
  • MF C225H348N48O68
  • MW 4813.45
Qhagamshelana nathi
iinkcukacha zemveliso

Inkcazo eneenkcukacha

I-Tirzepatide liyeza elinoveli elisetyenziselwa ukulawula ubunzima bexesha elide kwizigulana ezityebileyo ngokutyeba kwabantu abadala okanye i-comorbidities ezinxulumene nobunzima. I-agonist exhomekeke kwi-glucose ye-glucagon polypeptide (GIP) kunye ne-glucagon-like peptide-1 (GLP-1) receptors. Ivunywe yi-FDA ngo-2022, i-tirzepatide idibanisa iziphumo ze-enteric proinsulins kwi-molecule enye, iphucula ukukhutshwa kwe-insulin kunye nokunciphisa amanqanaba eglucagon. Eli nqaku liphonononga indlela yokusebenza, ukusebenza kweklinikhi, kunye neprofayili yokhuseleko lwe-tirzepatide njengonyango lokuncedisa ukunciphisa umzimba kunye nokuphucula ulawulo lwe-glycemic kwizigulane ezine-2 yeswekile.

I. Ukuqonda iTirzepatide:
A. I-agonist exhomekeke kwi-Glucose ye-GIP kunye ne-GLP-1 receptors
B. Inkqubo yesenzo: ukuphucula isigaba soku-I kunye nesigaba II se-insulin secretion, ukunciphisa amanqanaba eglucagon

II. Usetyenziso lweKlinikhi kunye neMvume ye-FDA:
A. Isalathiso: Ukulawulwa kwexesha elide lobunzima kwizigulane ezityebileyo kunye nokutyeba kwabantu abadala okanye ubunzima obunxulumene nobunzima
B. Unyango olongezelelweyo lokuphucula ulawulo lwe-glycemic kubantu abadala abanesifo sikashukela sohlobo lwe-2
C. Ukwamkelwa kwe-FDA kunye nokuthengiswa ngu-Eli Lilly ngo-2022

1715863859091roe

III. Ukusebenza kakuhle kuLawulo lobunzima:

A. Ukusebenza ngokuthelekisayo:

Ipesenti yokulahleka kwesisindo: Idosi ephantsi (5mg), idosi ephakathi (10mg), kunye nedosi ephezulu (15mg) amaqela

Umyinge weepesenti zokulahleka kobunzima kumaqela ahlukeneyo edosi

Ukuthelekisa neqela le-placebo

Ipesenti yezifundo ezifumana ukwehla kobunzima ngaphezu kwe-20%

B. Iprofayile yokhuseleko: Ukuphindaphinda kweempendulo ezingalunganga xa kuthelekiswa neqela le-placebo

C. Ukuthelekiswa namanye amayeza okunciphisa umzimba:

I-Orlistat (i-over-the-counter): Umahluko kwiipesenti zokulahlekelwa kwesisindo


IV. Indlela yoLawulo lweGlycemic kunye nokuLahla kobunzima:

A. Ukusetyenziswa kwe-GLP-1 kunye ne-GIP receptors

B. Ukunciphisa ukutya kunye nokunciphisa ukutya okutyayo



17158639023143ie


I-Tirzepatide, njenge-GLP-1 emibini kunye ne-GIP receptor agonist, ibonelela ngolawulo olusebenzayo lobunzima kunye nokuphuculwa kokulawulwa kwe-glycemic kwizigulane ezityebileyo kunye nokukhuluphala kwabantu abadala okanye ubunzima obunxulumene nobunzima, kunye nabantu abanesifo sikashukela sohlobo lwe-2. Indlela yokusebenza exhomekeke kwiglucose inyusa ukukhutshwa kwe-insulin kunye nokunciphisa amanqanaba eglucagon. Ngeepesenti ezibalulekileyo zokulahlekelwa kwesisindo kunye neprofayili ekhuselekileyo yokhuseleko, i-tirzepatide ivelele njengamayeza anamandla okulawula ubunzima bexesha elide. Uphando olongezelelweyo kunye nezifundo zeklinikhi ziyakuqhuba ziphonononga iinzuzo ezinokuthi zibekho kunye nokusetyenziswa kweli chiza lithembisayo.
Ukuze unikeze amava okurhweba angcono, sinokwenza i-capsule kunye neemveliso zolwelo, ngokweemfuno zakho zezithako.
Sinokwenza ngokwezifiso umthamo: 500mg / capsule, 550mg / capsule, 600mg / capsule.
Siyakwazi ukwenza ngokwezifiso ukupakishwa: 60 caps / ibhotile, 90 caps / ibhotile, 120 caps / ibhotile.
Sinokwenza ngokwezifiso iigobolondo ze-capsule kunye nemibala: iigobolondo ze-capsule yezityalo, iigobolondo ze-gelatin capsule.

Inkcazo

1715845381118yxs